Benjamin Maiser

Papers

Total Citations

H-Index

About

Benjamin Maiser is a researcher whose work has advanced the optimization of biopharmaceutical manufacturing, with a particular focus on protein PEGylation—a critical process for improving the efficacy and stability of therapeutic drugs. His most cited paper, "Optimization of random PEGylation reactions by means of high throughput screening" (2013, 44 citations), addresses a key challenge in the field: since the first FDA-approved PEGylated product in 1990, random PEGylation has remained the dominant technology for modifying biopharmaceuticals, yet its efficiency is highly sensitive to process parameters. Maiser’s contribution lies in demonstrating how high-throughput screening can systematically identify optimal reaction conditions, thereby enhancing the reproducibility and scalability of these modifications. This work has implications for the development of safer, more effective PEGylated drugs, a class that includes widely used treatments for cancer and chronic diseases. By bridging the gap between laboratory-scale optimization and industrial application, Maiser has provided a practical framework that supports both academic researchers and pharmaceutical developers. His research underscores the importance of process control in bioconjugation chemistry, offering a pathway to more consistent and cost-effective production of next-generation biologics.